Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.